ABSTRACT
Studies of the epidemiology of osteoporosis and of drug treatments for it have challenged the concept that denser bone means stronger bone. Bone strength or resistance to fracture is not easily measured by routine densitometry, being a function of both density and quality.
Footnotes
↵* The author has disclosed that he has received honoraria from the Eli Lilly, Merck, and Novartis companies for teaching and speaking.
- Copyright © 2009 The Cleveland Clinic Foundation. All Rights Reserved.
- Director, Center for Space Medicine
- Consultant, Departments of Biomedical Engineering and Endocrinology, Diabetes, and Metabolism, Metabolic Bone Center, Cleveland Clinic
- Editor-in-Chief, Clinical Reviews in Bone and Mineral Metabolism
- Editor-In-Chief, National Osteoporosis Foundation Osteoporosis Clinical Updates
- ADDRESS:
Angelo Licata, MD, PhD, Department of Endocrinology, A53, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail licataa{at}ccf.org.
ABSTRACT
Studies of the epidemiology of osteoporosis and of drug treatments for it have challenged the concept that denser bone means stronger bone. Bone strength or resistance to fracture is not easily measured by routine densitometry, being a function of both density and quality.
Footnotes
↵* The author has disclosed that he has received honoraria from the Eli Lilly, Merck, and Novartis companies for teaching and speaking.
- Copyright © 2009 The Cleveland Clinic Foundation. All Rights Reserved.